U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma
MELBOURNE, Australia, June 13, 2025 /PRNewswire/ -- On 7 May 2025, the FDA approved an IND application enabling Myrio's lead product (PHOX2B PC-CAR T) to enter human trials. Myrio, in collaboration the leading children's hospital in Philadelphia...
YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)
SHANGHAI, June 6, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's...
KIND Presents Preclinical Results of AND017 in Animal Models of Sickle Cell Disease (SCD), Myelodysplastic Syndromes (MDS), and β-Thalassemia at the 66th American Society of Hematology Meeting and Exposition and Announces FDA Authorization of Investigatio
SAN FRANCISCO, Dec. 12, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological...